Free shipping on all orders over $ 500
| Cat.No. | Name | Information |
|---|---|---|
| M6699 | EDTA | EDTA is a chelating agent. EDTA can activate NOTCH1 signaling. |
| M25077 | Tarlatamab | Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. |
| M24764 | Navicixizumab | Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. |
| M24736 | Rovalpituzumab | Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). |
| M24681 | Brontictuzumab | Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma. |
| M24627 | Tarextumab | Tarextumab (OMP-59R5) is an anti-Notch2/3 fully human IgG2 monoclonal antibody. Tarextumab shows anti-tumor activity. |
| M24588 | Demcizumab | Demcizumab (OMP 21M18) is an anti-DLL4 monoclonal antibody. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. |
| M14575 | RBPJ Inhibitor-1 | RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation. |
| M14574 | Notch inhibitor 1 | Notch inhibitor 1 is a potent Notch inhibitor, with IC50s of 7.8 and 8.5 nM for Notch 1 and Notch 3, respectively. Used in the research of cancer. |
| M14572 | Jagged-1 (188-204) (TFA) | Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells. |
| M14571 | IMR-1A | IMR-1A, a acid metabolite of IMR-1, is a Notch inhibitor with an IC50 of 0.5 μM. IMR-1A has a 50-fold increase in potency with respect to IMR-1. IMR-1 can metabolize in vivo to IMR-1A. |
| M14570 | Carvacrol | Carvacrol is a monoterpenoid phenol isolated from Lamiaceae family plants, with antioxidant, anti-inflammatory and anticancer properties. |
| M14569 | Bruceine D | Bruceine D is a Notch inhibitor with anti-cancer activity and induces apoptosis in several human cancer cells. |
| M11280 | Z-Ile-Leu-aldehyde | Z-ile-leu-aldehyde (Z-IL-Cho) is a potent and competitive peptide-aldehyde inhibitor of gamma-secretase and Notch. |
| M10373 | CB-103 | CB-103 is a first-in-class, orally active inhibitor of the Notch transcription activation complex. CB-103 inhibits Notch signaling in primary human T cell acute lymphoblastic leukemia and other Notch-dependent human tumor cell lines, and concomitantly induces cell cycle arrest and apoptosis. |
| M10088 | NVS-ZP7-4 | NVS-ZP7-4 is a potent ZIP7 Inhibitor, which inhibits Notch signaling with IC50 of 0.13 uM in HES-Luc reporter gene assays, selectively induces apoptosis and ER stress. |
| M8679 | IMR-1 | IMR-1 is a cell penetrant and potent inhibitor of Notch transcriptional activation complex that disrupted the recruitment of Mastermind-like 1 (Maml1) to the Notch transcriptional activation complex on chromatin. |
| M7667 | BMS-906024 | BMS-906024 is a γ-secretase inhibitor and pan-Notch inhibitor with IC50 values of 1.6 nM, 0.7 nM, 3.4 nM, and 2.9 nM for Notch1, 2, 3, and 4 receptors, respectively. BMS-906024 has antineoplastic activity. |
| M6699 | EDTA | EDTA is a chelating agent. EDTA can activate NOTCH1 signaling. |
| M4553 | Tangeretin | Tangeretin is a flavonoid from citrus fruit peels, and is also selected as a Notch-1 inhibitor, which plays an important role in anti-inflammatory responses and neuroprotective effects in several disease models. |
| M2828 | LY900009 | LY900009 is a potent, first-in-class Notch inhibitor with IC50 of 0.27 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.
